Kai Wille

1.5k total citations · 1 hit paper
39 papers, 355 citations indexed

About

Kai Wille is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Kai Wille has authored 39 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Genetics and 12 papers in Hematology. Recurrent topics in Kai Wille's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Eosinophilic Disorders and Syndromes (11 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Kai Wille is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Eosinophilic Disorders and Syndromes (11 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Kai Wille collaborates with scholars based in Germany, Austria and United States. Kai Wille's co-authors include Martin Grießhammer, Parvis Sadjadian, Tatjana Becker, Christiane Fuchs, Andrea Tannapfel, Thomas J. Ettrich, Anke Reinacher‐Schick, Hana Algül, Lukas Perkhofer and Thomas Seufferlein and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Kai Wille

34 papers receiving 351 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).

2024 37 citations Jens Hoeppner, Thomas Brunner et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kai Wille Germany	10	133	123	93	84	83	39	355
Leonardo Campiotti Italy	12	174 1.3×	78 0.6×	155 1.7×	52 0.6×	36 0.4×	22	443
Sandeep K. Rajan United States	11	65 0.5×	107 0.9×	128 1.4×	41 0.5×	58 0.7×	16	403
Pierre Brousset France	10	85 0.6×	296 2.4×	130 1.4×	37 0.4×	44 0.5×	23	582
PM Parikh India	10	58 0.4×	117 1.0×	113 1.2×	42 0.5×	120 1.4×	42	334
In Keun Choi South Korea	14	79 0.6×	128 1.0×	98 1.1×	83 1.0×	83 1.0×	36	420
Udomsak Bunworasate Thailand	12	158 1.2×	208 1.7×	189 2.0×	67 0.8×	18 0.2×	55	518
Amy Zhou United States	11	269 2.0×	69 0.6×	235 2.5×	89 1.1×	21 0.3×	24	529
Nicola Lucio Liberato Italy	9	171 1.3×	85 0.7×	147 1.6×	43 0.5×	24 0.3×	13	486
Alireza Fotouhi Ghiam Canada	13	59 0.4×	75 0.6×	44 0.5×	67 0.8×	98 1.2×	21	370
Tzung‐Chih Tang Taiwan	14	111 0.8×	146 1.2×	216 2.3×	37 0.4×	46 0.6×	33	507

Countries citing papers authored by Kai Wille

Since Specialization

Citations

This map shows the geographic impact of Kai Wille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Wille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Wille more than expected).

Fields of papers citing papers by Kai Wille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Wille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Wille. The network helps show where Kai Wille may publish in the future.

Co-authorship network of co-authors of Kai Wille

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Wille. A scholar is included among the top collaborators of Kai Wille based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Wille. Kai Wille is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wille, Kai, et al.. (2024). Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia. European Journal Of Haematology. 114(1). 17–25. 4 indexed citations

Al‐Batran, Salah‐Eddin, Sylvie Lorenzen, Jorge Riera, et al.. (2024). Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4001–LBA4001. 13 indexed citations

Hoeppner, Jens, Thomas Brunner, Florian Lordick, et al.. (2024). Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).. Journal of Clinical Oncology. 42(17_suppl). LBA1–LBA1. 37 indexed citations breakdown →

Seufferlein, Thomas, Ludwig Lausser, Alexander Stein, et al.. (2024). Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial. PLoS ONE. 19(6). e0304324–e0304324.

Modest, Dominik Paul, Volker Heinemann, Stefan Angermeier, et al.. (2024). Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116). Journal of Cancer Research and Clinical Oncology. 150(7). 332–332. 3 indexed citations

Wille, Kai, et al.. (2023). PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN). HemaSphere. 7(S3). e9728155–e9728155. 1 indexed citations

Wille, Kai, et al.. (2023). High‐resolution nerve ultrasound and corneal confocal microscopy in taxane‐induced polyneuropathy. European Journal of Neurology. 31(2). e16141–e16141. 4 indexed citations

Pilgram, Lisa, Maria J. G. T. Vehreschild, Martin Hower, et al.. (2023). Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. Infection. 51(4). 1033–1049. 6 indexed citations

Wille, Kai, et al.. (2023). Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. Hämostaseologie. 44(5). 386–392. 5 indexed citations

10.

Rüthrich, Maria Madeleine, Yascha Khodamoradi, Julia Lanznaster, et al.. (2023). COVID-19 in Patients with Active Cancer: Higher Inflammatory Activity Predicts Poor Outcome. Oncology Research and Treatment. 47(3). 88–96.

11.

Seufferlein, Thomas, Waldemar Uhl, Hana Algül, et al.. (2021). LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study. Annals of Oncology. 32. S1333–S1333. 5 indexed citations

12.

Pilgram, Lisa, Lukas Eberwein, Kai Wille, et al.. (2021). Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. Infection. 49(4). 725–737. 12 indexed citations

13.

Stegelmann, Frank, Kai Wille, Christiane Fuchs, et al.. (2020). Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia. 35(2). 628–631. 9 indexed citations

14.

Tometten, Lukas, Stefan Borgmann, Jochen Schneider, et al.. (2020). COVID-19 in cancer patients: Clinical characteristics and outcome - a first analysis of the LEOSS registry. Kölner Universitäts PublikationsServer (Universität zu Köln).

15.

Cremer, Sebastian, Carolin Jakob, Alexander Berkowitsch, et al.. (2020). Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clinical Research in Cardiology. 110(7). 1029–1040. 18 indexed citations

16.

Heidel, Florian H., Parvis Sadjadian, Tatjana Becker, et al.. (2020). Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. Journal of Cancer Research and Clinical Oncology. 147(5). 1481–1491. 6 indexed citations

17.

Sadjadian, Parvis, et al.. (2020). Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. Annals of Hematology. 100(8). 2015–2022. 17 indexed citations

18.

Ettrich, Thomas J., Anke Reinacher‐Schick, Hana Algül, et al.. (2018). A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma. Annals of Oncology. 29. viii663–viii663.

19.

Wille, Kai, et al.. (2018). High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Annals of Hematology. 98(1). 93–100. 25 indexed citations

20.

Ettrich, Thomas J., Andreas W. Berger, Lukas Perkhofer, et al.. (2018). Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 18(1). 1298–1298. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact